Mergers & Acquisitions ·
At its Annual General Meeting on June 30, 2026, Akari Therapeutics, Plc shareholders failed to re-elect James Neal to…
AKTXAkari Therapeutics Plc
At its Annual General Meeting on June 30, 2026, Akari Therapeutics, Plc shareholders failed to re-elect James Neal to the Board of Directors, ending his service as a director and his roles as Audit Committee member and Compensation Committee Chair. Consequently, the Board appointed Dr. Ray Prudo to the Audit Committee and Robert Bazemore as Chair of the Compensation Committee. Shareholders approved the issuance of ordinary shares under the ELOC Purchase Agreement, the issuance of Series H, I, and J Warrants for up to 4,411,764 ADSs, and a potential private placement resulting in a change of control. The company also authorized directors to allot shares up to a nominal amount of $20,000 through June 30, 2031. Akari Therapeutics is a biopharmaceutical company that develops therapies for inflammatory and immune-mediated diseases.